Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Apraclonidine. A one-week dose-response study.

H D Jampel1, A L Robin, H A Quigley

  • 1Glaucoma Services, Wilmer Ophthalmological Institute, Johns Hopkins University School of Medicine, Baltimore, MD.

Archives of Ophthalmology (Chicago, Ill. : 1960)
|August 1, 1988
PubMed
Summary

Apraclonidine hydrochloride effectively lowers elevated intraocular pressure (IOP) in a dose-dependent manner. Higher concentrations (0.25% and 0.5%) showed maximal IOP reduction, with minimal systemic effects observed.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Screening for vision-threatening diabetic retinopathy in South India: comparing portable non-mydriatic and standard fundus cameras and clinical exam.

Eye (London, England)·2017
Same author

Clinical outcomes of gamma-irradiated sterile cornea in aqueous drainage device surgery: a multicenter retrospective study.

Eye (London, England)·2016
Same author

Applying the resources and supports in self-management framework to examine ophthalmologist-patient communication and glaucoma medication adherence.

Health education research·2015
Same author

Neural dysfunction in ADHD with Reading Disability during a word rhyming Continuous Performance Task.

Brain and cognition·2015
Same author

Selective loss of pattern discrimination in early glaucoma.

Applied optics·2010
Same author

Impact of adjuvant chemotherapy on glaucoma filtration surgery.

Journal of glaucoma·2009

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Elevated intraocular pressure (IOP) is a significant risk factor for glaucoma.
  • Pharmacological interventions are crucial for managing IOP and preventing vision loss.

Purpose of the Study:

  • To evaluate the dose-response relationship of apraclonidine hydrochloride in reducing elevated IOP.
  • To assess the efficacy and safety of different apraclonidine concentrations.

Main Methods:

  • A double-masked, cross-over, dose-response study was conducted.
  • Twenty patients with elevated IOP received three concentrations of apraclonidine (0.125%, 0.25%, 0.5%) and vehicle control.
  • IOP, pupillary diameter, interpalpebral fissure width, blood pressure, and pulse were monitored over time.

Main Results:

Related Experiment Videos

  • All apraclonidine concentrations significantly reduced IOP compared to vehicle.
  • 0.5% and 0.25% apraclonidine demonstrated maximal IOP reduction (average 27% decrease, 8.7 mm Hg).
  • Higher concentrations were more effective than 0.125% at 2 and 8 hours; interpalpebral fissure width increased dose-dependently.

Conclusions:

  • Apraclonidine hydrochloride is an effective agent for lowering elevated IOP.
  • The 0.25% and 0.5% concentrations provide significant IOP reduction with minimal systemic side effects.
  • Transient dry nose or mouth were reported, potentially dose-dependent.